千金药业
(600479)
| 流通市值：47.29亿 | | | 总市值：48.47亿 |
| 流通股本：4.19亿 | | | 总股本：4.29亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,798,485,330.31 | 2,778,909,669.96 | 1,912,806,548.25 | 960,198,380.73 |
| 营业收入 | 3,798,485,330.31 | 2,778,909,669.96 | 1,912,806,548.25 | 960,198,380.73 |
| 二、营业总成本 | 3,356,217,415.98 | 2,501,532,388.65 | 1,748,305,358.63 | 893,304,025.53 |
| 营业成本 | 2,046,728,898.67 | 1,498,058,790.74 | 1,051,466,437.84 | 534,831,413.59 |
| 税金及附加 | 38,002,022.56 | 28,179,074.29 | 18,886,110.98 | 9,546,993.95 |
| 销售费用 | 904,270,042.72 | 701,809,125.67 | 502,821,665.02 | 268,700,778.36 |
| 管理费用 | 263,579,443.06 | 196,717,154.68 | 126,496,773.84 | 55,130,436.71 |
| 研发费用 | 149,067,057.97 | 111,291,724.78 | 60,693,773.62 | 23,884,290.27 |
| 财务费用 | -45,430,049 | -34,523,481.51 | -12,059,402.67 | 1,210,112.65 |
| 其中:利息费用 | 1,668,222.98 | 2,246,966.82 | 1,968,453.17 | 1,319,617.93 |
| 其中:利息收入 | 51,394,739.11 | 38,945,512.82 | 15,465,898.25 | 1,872,507.75 |
| 加:公允价值变动收益 | -1,597,097.03 | -3,957,953.85 | -5,090,050.04 | -1,277,029.2 |
| 加:投资收益 | 17,469,067.27 | 11,405,977.82 | 11,603,222.61 | 4,717,099.68 |
| 资产处置收益 | - | 0 | 0 | 0 |
| 资产减值损失(新) | -2,571,229.74 | -162,939.82 | -162,939.82 | 0 |
| 信用减值损失(新) | -18,269,569.55 | -14,226,451.57 | -11,340,563.46 | -11,029,295.89 |
| 其他收益 | 24,640,571.39 | 11,941,030.13 | 9,521,934.29 | 6,753,939.61 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 461,939,656.67 | 282,376,944.02 | 169,032,793.2 | 66,059,069.4 |
| 加:营业外收入 | 996,260.63 | 1,024,054.14 | 534,234.39 | 210,500.29 |
| 减:营业外支出 | 2,516,446.01 | 871,659.66 | 412,569.26 | 217,523.79 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 460,419,471.29 | 282,529,338.5 | 169,154,458.33 | 66,052,045.9 |
| 减:所得税费用 | 65,402,588.87 | 42,915,195.66 | 24,824,230.03 | 9,304,652.64 |
| 六、净利润 | 395,016,882.42 | 239,614,142.84 | 144,330,228.3 | 56,747,393.26 |
| 持续经营净利润 | 395,016,882.42 | 239,614,142.84 | 144,330,228.3 | 56,747,393.26 |
| 归属于母公司股东的净利润 | 320,405,834.89 | 196,908,205.04 | 116,711,091.4 | 43,906,688.63 |
| 少数股东损益 | 74,611,047.53 | 42,705,937.8 | 27,619,136.9 | 12,840,704.63 |
| (一)基本每股收益 | 0.76 | 0.46 | 0.27 | 0.1 |
| (二)稀释每股收益 | 0.76 | 0.46 | 0.27 | 0.1 |
| 八、其他综合收益 | 185,415.06 | 189,132.13 | -2,003.79 | 222.77 |
| 归属于母公司股东的其他综合收益 | 185,415.06 | 189,132.13 | -2,003.79 | 222.77 |
| 九、综合收益总额 | 395,202,297.48 | 239,803,274.97 | 144,328,224.51 | 56,747,616.03 |
| 归属于母公司股东的综合收益总额 | 320,591,249.95 | 197,097,337.17 | 116,709,087.61 | 43,906,911.4 |
| 归属于少数股东的综合收益总额 | 74,611,047.53 | 42,705,937.8 | 27,619,136.9 | 12,840,704.63 |
| 公告日期 | 2024-04-12 | 2023-10-28 | 2023-08-25 | 2023-04-29 |
| 审计意见(境内) | 标准无保留意见 | | | |